Review Article

Human Long Noncoding RNA Regulation of Stem Cell Potency and Differentiation

Seahyoung Lee,1 Hyang-Hee Seo,2 Chang Youn Lee,3 Jiyun Lee,2 Sunhye Shin,3 Sang Woo Kim,1 Soyeon Lim,1 and Ki-Chul Hwang1

1Institute for Biomedical Convergence, College of Medicine, Catholic Kwandong University, Gangneung-si, Gangwon-do, Republic of Korea
2Brain Korea 21 PLUS Project for Medical Science, Yonsei University, Seoul, Republic of Korea
3Department of Integrated Omics for Biomedical Sciences, Yonsei University, Seoul, Republic of Korea

Correspondence should be addressed to Soyeon Lim; slim724@cku.ac.kr and Ki-Chul Hwang; kchwang@cku.ac.kr

Received 27 April 2017; Revised 12 July 2017; Accepted 2 August 2017; Published 30 August 2017

Academic Editor: Mark W. Hamrick

Copyright © 2017 Seahyoung Lee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Because of their capability of differentiation into lineage-specific cells, stem cells are an attractive therapeutic modality in regenerative medicine. To develop an effective stem cell-based therapeutic strategy with predictable results, deeper understanding of the underlying molecular mechanisms of stem cell differentiation and/or pluripotency maintenance is required. Thus, reviewing the key factors involved in the transcriptional and epigenetic regulation of stem cell differentiation and maintenance is important. Accumulating data indicate that long noncoding RNAs (lncRNAs) mediate numerous biological processes, including stem cell differentiation and maintenance. Here, we review recent findings on the human lncRNA regulation of stem cell potency and differentiation. Although the clinical implication of these lncRNAs is only beginning to be elucidated, it is anticipated that lncRNAs will become important therapeutic targets in the near future.

1. Introduction

Stem cells are specialized cells capable of differentiating into lineage-specific cells. Depending on their potential to differentiate and source of origin, stem cells can be broadly categorized into embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), and adult stem cells such as bone marrow mesenchymal stem cells (BM-MSCs) and adipose-derived stem cells (ADSCs). Due to their differentiation and self-renewal abilities, stem cells have been highly regarded as an effective therapeutic modality in regenerative medicine [1]. Effective stem cell therapeutics should be based on a meticulously designed strategy, especially if the goal of stem cell-based therapy involves in situ differentiation of stem cells. In other words, to develop an effective stem cell-based therapeutic strategy with predictable results, deeper understanding of the underlying molecular mechanisms of stem cell differentiation and/or pluripotency maintenance is required. Therefore, it is worth reviewing the key factors involved in the transcriptional and epigenetic regulation of stem cell differentiation and maintenance. One of such key factors of stem cell biology is a group of noncoding RNAs (ncRNAs) [2, 3].

A large portion of the human genome is transcribed into RNAs without coding proteins. Noncoding RNAs are such RNAs that are not translated into proteins. Based on their sizes, they can be classified into the following 2 categories: small ncRNAs and long ncRNAs. Small ncRNAs refer to ncRNAs shorter than 200 nucleotides long, while long ncRNAs (lncRNAs) refer to ncRNAs composed of 200 or more nucleotides. Small ncRNAs can be further categorized into subcategories based on their length, function, and subcellular localization such as microRNAs (miRNAs), short interfering RNAs (siRNAs), Piwi-interacting RNAs (piRNAs), small nucleolar RNAs (snoRNAs), short hairpin RNAs (shRNA), and other short RNAs [4, 5]. These small ncRNAs have been implicated in stem cell biology, and many excellent articles on the role of these small ncRNAs in stem cell biology
are already available [6–8]. Therefore, only the lncRNAs with documented functions affecting human stem cell biology will be discussed in this particular review.

2. General Regulatory Mechanisms of lncRNA

lncRNAs are a class of RNAs that do not encode proteins but participate in multiple biological processes. Thanks to the advanced RNA sequencing technology, the number of sequence-verified lncRNAs is rapidly increasing [9]. The transcriptional process of lncRNAs is the same as that of protein-coding messenger RNAs (mRNAs). RNA polymerase II (PolII) transcribes lncRNAs from genomic loci, and the transcribed lncRNAs are frequently 5′ capped, spliced, and polyadenylated [10]. Except few specific characteristics of lncRNAs (lack of translated open reading frames, relatively shorter length, and poor conservation of primary sequence [11]), there is no known fundamental biochemical difference between messenger RNAs (mRNAs) and lncRNAs. A recent review authored by Quinn and Chang can provide more information on the general lifecycle of lncRNAs and known functions in depth [12]. Accumulating data indicates that lncRNAs mediate numerous regulatory processes such as imprinting genomic loci, chromosomal conformation, and allosteric regulation of enzyme activity [13, 14]. LncRNA-mediated regulatory mechanisms are diverse, and few examples of the regulatory mechanisms of lncRNAs are described in Figure 1.

In cytoplasm, lncRNAs can regulate gene expression by modulating turnover, translation, or suppression of partially complementary mRNAs [15]. It has been reported that a double-stranded structure formed by the interaction between the Alu elements of lncRNAs and the complementary Alu elements in the 3′ untranslated region of an mRNA facilitates Staufen-mediated mRNA turnover [16]. As an example of lncRNA-mediated mRNA translation, it has been reported that lncRNA containing short interspersed nuclear elements B2 (SINEB2) repeats increased ubiquitin carboxy-terminal hydrolase L1 (Uchh1) mRNA translation through association with the 5′ region [17]. LncRNAs can also block miRNA-mediated silencing of an mRNA by masking the miRNA-binding sites on a target mRNA [18]. Some lncRNAs can act as a sponge for endogenous miRNAs, neutralizing miRNA-mediated silencing of mRNAs [19, 20]. LncRNA-mediated signaling pathway modulation in cytoplasm also has been reported. According to a previous study, NF-kappaB interacting LncRNA (NKILA) inhibits NF-κB signaling by masking the IkB phosphorylation sites of NF-κB/IkB complex, stabilizing the complex [21].

Nuclear lncRNAs can act as an epigenetic regulator or a guide by recruiting chromatin modification factors to locus. For example, lncRNA PVT1 has been reported to recruit enhancer of zeste homolog 2 (EZH2, a histone modifying enzyme) to the large tumor suppressor kinase 2 (LATS2) promoter, repressing LATS2 transcription [22]. As scaffolds, nuclear lncRNAs bring together multiple proteins to form ribonucleoprotein (RNP) complexes. Such lncRNA-RNP complexes can either affect histone modifications or stabilize signaling complexes or nuclear structures [23]. Another way of nuclear lncRNA facilitating gene expression is acting as decoys. Decoy lncRNAs modulate transcription by sequestering regulatory factors such as transcription factors and catalytic proteins, rendering them less available for transcription [24]. Additionally, lncRNAs can regulate mRNA splicing process. For example, metastasis-associated lung adenocarcinoma transcript 1 (MALAT-1) regulates alternative splicing by modulating the phosphorylation of serine/arginine splicing factors [25].

3. Human lncRNA in Stem Cells

During the last few years, a number of good reviews on the role of lncRNAs in stem cell biology have been published [2, 26–28]. However, those previous reviews were not specific to the lncRNAs reported to exist in human. Although animal models (i.e., mouse) provide us a great deal of information that can be directly applied to human biology, not all the information obtained from animal studies can be applied to humans. In fact, studies have indicated that lncRNAs are less conserved than protein-coding genes [11, 29]. According to a previous study conducted a clone-based genome assembly of mouse, only a small portion of mouse lncRNAs had evidence of human expression [30]. This particular study indicated that only half of the mouse lncRNA sequences (1538 out of 3051 mouse lncRNAs documented) could be mapped to the human genome assembly, and furthermore, only 14% of the mouse lncRNA sequences (439 out of 3051 mouse lncRNAs documented) had evidence of orthologous transcription in human based on expressed sequence tag (EST) or cDNA. Of course, those lncRNAs lacking evidence of human orthologs may be simply unidentified in humans as yet. However, it is still worth summarizing lncRNAs identified in human stem cells considering that one of the major purposes of studying stem cell regulation is to develop more effective clinical strategies utilizing stem cells. Therefore, this review deals with the lncRNAs (1) whose regulatory function has been confirmed in human stem cells or (2) whose existence has been verified in human and the function of its orthologs from other species has been reported in stem cells.

3.1. Eosinophil Granule Ontogeny (EGO)

In 2007, Wagner and colleagues first identified EGO as a long noncoding RNA nested within an intron of inositol triphosphate receptor type 1 (ITPR1) by demonstrating that EGO transcript was not associated with ribosomes [31]. According to their study, the transcript level of EGO increased during interleukin-5- (IL-5-) induced eosinophil differentiation of human CD34+ hematopoietic stem cells from healthy donors. Silencing EGO subsequently decreased the mRNA expression of major basic protein (MBP) and eosinophil-derived neurotoxin (EDN), suggesting that EGO was required to maintain normal level of MBP and EDN during eosinophilopoiesis of umbilical cord blood CD34+ cells. EGO acting as a small interfering RNA (siRNA) or protecting mRNAs from degradation by forming an RNA-protein complex has been proposed as possible mechanisms.
3.2. Gomafu (Alias: MIAT or RNCR2). In 2004, retinal non-coding RNA 2 (RNCR2) was first reported in the developing retina of mouse with nuclear- or perinuclear-localized expression pattern [32]. More recent study reported that nuclear-localized RNCR2 regulates retinal cell specification acting as a suppressor of differentiation into amacrine inter-neurons and Müller glia cells [33]. In between those two studies mentioned above, Sone and colleagues reported a noble mRNA-like noncoding gene named Gomafu (meaning “spotted pattern” in Japanese) as a neuron-specific component of the nuclear matrix [34]. They found that Gomafu shares homologous region with RNCR2 and that human homologous sequence was located in a syntenic region of chromosome 22q12. As to the role of Gomafu in stem cell biology, it has been suggested that Gomafu and Oct4 establish an autofeedback loop to maintain pluripotency of mouse stem cells.

Figure 1: Schematic diagram of lncRNA-mediated regulatory mechanism. In cytoplasm, (A) lncRNAs can regulate turnover, translation, and silencing of partially complementary mRNAs. (B) lncRNAs can act as a miRNA sponge, reducing miRNA availability. (C) lncRNAs can modulate signaling pathways by interacting with signaling molecules. In nucleus, (D) nuclear lncRNAs can be decoys for regulatory proteins such as transcription factor. (E) Nuclear lncRNAs can serve as a scaffold for RNA-protein complex. RNP: ribonucleoprotein. (F) Nuclear lncRNAs can be an epigenetic regulator by recruiting chromatin modification factors.
embryonic stem cells (mESCs) [35]. RNAi-mediated down-regulation of Gomafu led to downregulation of Oct4, along with decreased expression of Oct4-driven pluripotency markers, such as Sox2, Klf4, Gdf3, Fgf4, and Dppa3/Stella. On the other hand, RNAi specific to Gomafu increased the expression of trophoblast markers such as Cdx2, Hand1, Eomes, and Gata3 [36–38], suggesting a possible role of Gomafu as an endogenous inhibitor of differentiation along the trophoblast lineage.

Gomafu was also involved in neurogenesis and oligodendrocyte (OL) lineage specification of neural stem cells (NSCs) [39]. Gradient of sonic hedgehog (Shh) signaling promotes differentiation of nestin-positive NSC in the ventral forebrain into bipotent Nkx2.1-expressing bipotent neuronal-OL progenitor (N/OP) that can be further differentiated into GABAergic neurons (GABANs) and OLs [40]. During basic fibroblast growth factor (bFGF) and N-terminal active form of sonic hedgehog- (N-Shh-) induced N/OP differentiation of NSCs, Gomafu was downregulated but increased again in OL lineage specification and maturation [39]. However, the underlying mechanisms of Gomafu regulation or functional consequences have not been elucidated. Another alias of Gomafu is myocardial infarction-associated transcript (MIAT) [41]. A very recent study reported that knockdown of MIAT promoted osteogenic differentiation of human adipose-derived stem cells (hASCs), suggesting its role as an endogenous suppressor of osteogenic differentiation of stem cells [42]. Nevertheless, the underlying mechanisms remain unexplored.

3.3. Embryonic Ventral Forebrain 2 (Evf2). Evf2 is an antisense lncRNA to distal-less homeobox 6 (Dlx-6) genes of Dlx-5/6 cluster, and it forms a complex with Dlx-2 to increase the activity of Dlx-5/6 enhancer during neurogenesis [43]. Evf2 is transcribed from the Dlx-5/6 intergenic enhancer elements and transcripts analysis using human EST database indicated that it is conserved in human. Although no specific function of Evf2 in stem cell has been elucidated, it has been reported that its expression increased during GABAN differentiation of N/OP [39].

3.4. Metastasis-Associated Lung Adenocarcinoma Transcript 1 (MALAT-1). MALAT-1 is an oncogenic lncRNA conserved across several species including human and highly expressed in lung, pancreas, and non-small-cell lung cancer [44]. It was first reported in cancer, and accumulating data also indicate it plays significant roles in cancer stem cell biology. MALAT-1 has been reported to activate the transcription of latent-transforming growth factor beta-binding protein 3 (LTBP3), a transforming growth factor beta (TGF-β) bioactivity-regulating gene [45], by recruiting transcription factor Sp1 to the LTBP3 promoter in MSCs from myeloma patients [46]. The oncogenic role of MALAT-1 may be partially mediated by TGF-β production because TGF-β can promote tumor cell growth by triggering interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF) production [47]. According to another study using human glioma stem cell line SHG139S, downregulation of MALAT-1 suppressed the expression of stemness markers such as Sox2 and Nestin, while it increased the proliferation of SHG139S by activating ERK/MAPK signaling [48]. Furthermore, MALAT-1 increased the proportion of chemotherapy-resistant pancreatic cancer stem cells with enhanced self-renewing capacity, and this was related to the increased expression of Sox2 [49]. A more recent study demonstrated that MALAT-1, with another IncRNA highly upregulated in liver cancer (HULC) [50], increased the expression of telomere repeat-binding factor 2 (TRF2) and accelerated liver cancer stem cell growth [51]. Such stemness and proliferation regulating role of MALAT-1 are reported in non-cancer stem cells such as iPSCs [52] and hematopoietic cells [53], as well.

3.5. H19. IncRNA H19 is the first lncRNA discovered, and it is paternally imprinted [54]. Human H19 is mapped to the H19-insulin-like growth factor 2 (IGF2) loci of chromosome 11p15.5. H19 transcribes a 2.3kb IncRNA composed of 5 exons. From the first exon, H19 transcript produces the oncomir miR-675-5p and miR-675-3p [55]. MiR-675 is known to be expressed exclusively in the gestational placenta inhibiting placental growth [56]. The expression of miR-675 and H19 has been verified in human cells [57, 58]. The first evidence that H19 is involved in embryonic stem cell differentiation was reported in 1991. Poirier and colleagues demonstrated that H19 expression was activated during early murine embryogenesis [59]. Recently, the role of H19-IGF2 locus in adult hematopoietic stem cell (HSC) quiescence was reported. Maternal-imprinted H19-derived miR-675 suppresses IGF2-IGFRI signaling pathway leading to Foxo3-mediated cell cycle arrest. This causes adult HSC quiescence which is required for long-term maintenance of HSC [60].

3.6. HOX Antisense Intergenic RNA Myeloid 1 (HOTAIRM1). HOTAIRM1 was discovered as a myeloid-specific intergenic IncRNA of human HOXA1 and HOXA2 [61]. In their study, Zhang and colleagues reported that HOTAIRM1 was upregulated during granulocyte differentiation of human HSCs in a myeloid lineage-specific manner. Furthermore, knockdown of HOTAIRM1 attenuated the expression of CD11b and CD18, well known myeloid cell markers [62], suggesting HOTAIRM1 is an important mediator of myeloid cell differentiation.

3.7. Maternally Expressed Genes 3 (MEG3). Another human-imprinted gene MEG3 is located in the delta-like homolog 1 gene and type III iothalamide deiodinase (DLK1-DIO3) locus on human chromosome 14q [63]. MEG3 is expressed in normal tissues but downregulated by aberrant DNA methylation in human cancers implying its role as a tumor suppressor [64, 65]. Genomic imprinting of MEG3 is unstable in human ESCs [66], as well as in iPSCs [67]. According to the study conducted by Mo and colleagues, human ESCs with low MEG3 expression level (designated as MEG3-OFF) also showed significantly low expressions of DLK1-DIO3 locus-derived noncoding RNAs, including MEG8, miR-127, miR-376, miR-494, miR-495, miR-496, and miR-154, compared to its counterpart MEG3-ON [68]. Further,
they demonstrated that MEG3-OFF led to suppressed expression of neural lineage markers such as PAX6, RTN1, and Sox11, suggesting its role as a positive regulator of neuronal differentiation.

Another known function of MEG3 is to recruit polycomb repressive complex 2 (PRC2) to chromatin to maintain transcriptional repression of lineage-specific genes during development. PRC2 is responsible for the di- and trimethylation of lysine 27 in histone H3 (H3K27me2/3) [69], which is one of the important characteristics of inactive heterochromatin [70]. MEG3 recruits PRC2 to chromatin via interaction with jumonji family, ARID domain-containing protein 2 (JARID2) [71]. Chromatin-bound JARID2 further interacts with MEG3 forming a scaffold for maximum PRC2 recruitment. Subsequently, PRC2 is recruited and assembled with MEG3 during ESC differentiation. This suggests that MEG3 is an important factor in epigenetic regulation of lineage-specific genes during ESC differentiation.

Additionally, MEG3 has been implicated in osteogenic differentiation of stem cells, but the results have been inconsistent depending on the source of stem cells. First, MEG3 has been reported to promote osteogenic differentiation of MSCs from multiple myeloma patients by releasing sex-determining region Y box 2- (SOX2-) mediated transcriptional suppression of bone morphogenetic protein 4 (BMP4) promoter [72]. However, few years later, the anti-osteogenic effect of MEG3 in bone marrow MSCs of postmenopausal osteoporosis patient by increasing the expression of miR-133a-3p was reported [73]. Although the mechanism of such discrepancy still remains unclear, disease type-dependent effect is suspected.

3.8. Nuclear-Enriched Abundant Transcript 1 (NEAT1). As the full name indicates, NEAT1 is frequently observed in nuclei, especially in the subnuclear body called paraspeckles [74]. Paraspeckles were first identified as a distinct form of nuclear structure different from the nuclear speckles that are enriched in splicing factors [75]. Paraspeckles regulate the expression of genes in differentiated cells by nuclear retention of mRNAs. The formation of paraspeckles around NEAT1 has been reported by several groups [74, 76, 77]. Paraspeckles are only observed in mammalian cells, including primary cell lines and embryonic fibroblasts [78, 79]. However, paraspeckles are not present in undifferentiated human embryonic stem cells but are induced upon differentiation [76]. Other than the role as a mediator of RNA retention, NEAT1 has been implicated in the adipogenic differentiation of ADSCs into adipocytes. Mature miR-140 interacts with NEAT1 in the nucleus, and this subsequently increases NEAT1 expression leading to adipogenesis [80]. However, they only demonstrated that miR-140-mediated NEAT1 expression is required for adipogenesis, without providing the underlying mechanism of how the increased NEAT1 contributed to adipogenesis.

3.9. LincRNA-Regulator of Reprogramming (LincRNA-RoR). LincRNA-RoR was first identified as an IncRNA enriched in human iPSCs and suspected as a modulator of chromatin complexes to regulate pluripotent cell-specific epigenetic architecture [81]. Another study demonstrated that lincRNA-RoR functioned as a miRNA sponge for the miRNAs targeting embryonic stem cell-enriched transcription factors such as Oct4, Sox2, and Nanog. Consequently, lincRNA-RoR prevented miRNA-mediated suppression of these transcription factors, enhancing the self-renewal ability of human ESCs [82].

3.10. NoRC-Associated RNA (Promoter-Associated RNA, pRNA). Promoter-associated RNAs were described in vitro in human [83]. Maturation of 250~300 nucleotide long pRNA is achieved by processing 2 kb long intergenic spacer rRNA (IGS-rRNA) [84]. Regarding the role of pRNA in stem cells, it has been reported that mature pRNA mediated association between the nucleolar transcription terminator factor 1 (TTF1) and TTF1-interacting protein 5 (TIP5) was prerequisite to the generation of heterochromatin rDNA required for exit from pluripotency during ESC differentiation [85]. This indicated that mature pRNA may function as an initiator of ESC differentiation.

3.11. Antisense to Nitric Oxide Synthase 2A (Anti-NOS2A). Anti-NOS2A shares high antisense homology (approximately 80%) to the corresponding regions of NOS2A gene. It is speculated that the anti-NOS2A is a result of gene duplication followed by an internal DNA inversion [86]. The anti-NOS2A functions as a natural antisense transcript that regulates NOS gene expression. In mammalian brain, upregulation of NOS2A has been associated with neurogenesis suggesting that NOS-mediated endogenous NO production is important in neuronal differentiation [87]. In line with such findings, the expression of anti-NOS2A significantly decreased in neurons compared to that in undifferentiated human ESCs, while the expression of NOS2A showed an opposite pattern [86]. This indicated that anti-NOS2A may act as a neuronal differentiation suppressor in ESCs.

3.12. Small Nucleolar RNA Host Gene 3 and 1 (SNHG3 and SNHG1). Pertaining to the role of SNHG3 in stem cells, it has been reported that SNHG3 is one of the 26 IncRNAs that are required to maintain the pluripotency program of ESCs [88]. More specifically, knockdown of SNHG3 in ESCs significantly decreased the expressions of pluripotency markers including Oct4, Sox2, Nanog, Klf4, and Zfp43. Furthermore, the expression level of SNHG3 was downregulated during retinoic acid-induced differentiation of ESC, indicating that SNHG3 was one of the IncRNAs that regulate pluripotency program of ESCs. As the underlying mechanism, an ESC state controlling circuitry was proposed where ESC-specific transcription factors (e.g., Oct4, Sox2, and Nanog) derive the transcription of SNHG3, and the produced SNHG3 forms an RNA-protein complex that represses cell type-specific gene expression program. As to the role of SNHG1, it has been reported that the expression of SNHG1 significantly increased during lineage restriction of NSCs (neural stem cells) into N/OPs (bipotent neuronal/oligodendrocyte progenitors) [39]. Recent studies indicated that both SNHG1
and SNHG3 were highly correlated with poor prognosis in cancer patients [89, 90].

3.13. SOX2 Overlapping Transcript (SOX2OT). SOX2 is a HMG-box transcription factor contributes to the maintenance of pluripotency of undifferentiated ESCs [91]. In humans, approximately 700 kb long SOX2OT gene is mapped to chromosome 3q26.3 locus and the SOX2 gene is embedded in the intronic region of SOX2OT; therefore, it gets its name [92]. Concomitant upregulation of SOX2 and SOX2OT in ESCs, which decreased upon differentiation, has been reported [93], and SOX2OT functioning as an enhancer to the transcription of SOX2 was postulated as the possible underlying mechanism [94]. These reports indicate that SOX2OT modulates pluripotency of stem cells via regulation of SOX2.

3.14. VLDLR Antisense RNA1 (LincRNA-VLDLR). LincRNA-VLDLR was first identified as one of the IncRNAs significantly upregulated in human iPSCs and ESCs [81]. According to that particular study, pluripotency-regulating transcription factors such as Oct4, Sox2, and Nanog colocalized on the promoter of the lincRNA-VLDLR, suggesting pluripotency-regulating transcription factors induce the expression of lincRNA-VLDLR, and in turn, lincRNA-VLDLR regulates the maintenance of pluripotency. However, no specific target of the lincRNA-VLDLR has been identified regarding the maintenance of stem cell pluripotency [95].

3.15. Cardiac Mesoderm Enhancer-Associated Noncoding RNA (CARMEN). CARMEN was first characterized by Ounzain and colleagues as an IncRNA associated with human cardiac-specific enhancer [96]. Enhancers are an important regulatory sequences within the genome that integrates temporal, spatial, and environmental cues to regulate gene expression [97]. Enhancer-associated noncoding RNAs play important roles in heart development and disease [98]. CARMEN, as one of such enhancer-associated noncoding RNAs, is crucial for cardiac specification and differentiation of human cardiac progenitor cells (CPCs), and this was evidenced by the observation that knockout of CARMEN inhibited cardiac specification and differentiation of human CPCs [96].

3.16. Rhabdomyosarcoma 2-Associated Transcript (RMST). RMST was first identified as an IncRNA significantly upregulated upon neuronal differentiation of human ESCs [99]. A year later, the same group elucidated the underlying mechanism of RMST in neuronal differentiation. The expression of RMST was suppressed by RE1-silencing transcription factor (REST), a master negative regulator of neuronal differentiation [100], in undifferentiated human ESCs but increased upon neuronal differentiation of human ESCs. Furthermore, nuclear localized RMST during neuronal differentiation bound to hnRNPA2/B1, a ubiquitous RNA-binding protein [101], and Sox2. Binding of RMST to Sox2 promoted Sox2 binding at the promoters of neurogenic genes, such as achaete-scute homolog 1 (ASCL1 [102]) and distal-less homeobox 1 (DLX-1 [103]), driving neuronal differentiation of human ESCs [104].

3.17. Human Endogenous Retrovirus Subfamily H (HERVH). HERVH is a transposable element preferentially expressed in human ESCs. It has been reported that the long terminal repeats of HERVH regulated the expression of neighboring pluripotency marker genes by binding to both Oct4 and coactivators such as p300 in human ESCs [105].

4. Possible Clinical Applications of the IncRNAs in Stem Cells

The research on roles of IncRNAs in stem cell biology is still in its infancy. Furthermore, only few cell therapies using stem cells have demonstrated satisfying clinical benefit to warrant their clinical use [106]. In other words, both the research on the IncRNAs in stem cells and the cell therapies using stem cells are far from being completed. Therefore, it is very difficult to discuss the clinical implications of IncRNAs in stem cells in depth. However, approximately half million single nucleotide polymorphisms (SNPs) in more than 30,000 human IncRNAs have been identified already [107], and this strongly suggests high possibility of dysregulated IncRNAs even in stem cells. It has been demonstrated that dysregulation of IncRNAs contributes to numerous human diseases, and even very simple mutations such as SNPs can have tremendous consequences in terms of IncRNA structure and function [108].

Assuming one of the major purposes of studying the stem cell biology is to design more effective cell therapy approaches, dysregulated IncRNAs in stem cells can be a selection marker for screening adequate stem cells for transplantation. Another possible application of IncRNAs in stem cells is to use IncRNAs as a therapeutic target for reinforcing stem cell function. For example, gene-editing technology can be utilized to facilitate in situ differentiation of stem cells into desired lineage of cells by editing IncRNAs that promote or suppress differentiation of stem cells. Additionally, finding and using small molecule that induces or inhibits specific IncRNAs may serve as a powerful tool to enhancing the functionality of stem cells. However, these therapeutic applications of IncRNAs in stem cells can be realized only when the regulatory mechanisms of IncRNAs in stem cells are sufficiently elucidated.

5. Conclusions and Perspectives

An increasing number of studies have provided evidence that IncRNAs are important regulators of the differentiation and pluripotency maintenance of stem cells. Studies have demonstrated that IncRNAs modulate stem cell biology by interacting with essential transcription factors responsible for maintaining pluripotency or regulating differentiation. It is clear that IncRNAs play critical roles in different types of human stem cells with diverse mechanisms. Furthermore, the existence of dysregulated IncRNAs adds a new layer of complexity to the molecular mechanisms of human disease. Despite recent progress in this field, we still have a long way to fully comprehend the roles of these important regulators in human stem cells. Therefore, further studies are strongly required, and it is expected that future study of
lncRNAs in stem cells will provide us new therapeutic targets for the prevention and treatment of human disease.

Conflicts of Interest
The authors declare that there is no conflict of interest.

Authors’ Contributions
Seahyoung Lee and Hyang-Hee Seo equally contributed to this work.

Acknowledgments
This study was supported by grants funded by the Korea Ministry of Science, ICT and Future Planning (NRF-2015M3A9E6029519 and NRF-2015M3A9E6029407) and a grant from the Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea (A120478).

References
[1] R. S. Mahla, “Stem cells applications in regenerative medicine and disease therapeutics,” International Journal of Cell Biology, vol. 2016, Article ID 6940283, 24 pages, 2016.
[2] S. Hu and G. Shan, “LncRNAs in stem cells,” Stem Cells International, vol. 2016, Article ID 2681925, 8 pages, 2016.
[3] T. Lammins, I. D’Hont, K. D’Herde, Y. Benoît, and A. Diez-Fraile, “Long non-coding RNAs in pluripotent stem cell biology,” The Veterinary Quarterly, vol. 33, no. 4, pp. 202–206, 2013.
[4] T. Nagano and P. Fraser, “No-nonsense functions for long noncoding RNAs,” Cell, vol. 145, no. 2, pp. 178–181, 2011.
[5] C. P. Ponting, P. L. Oliver, and W. Reik, “Evolution and functions of long noncoding RNAs,” Cell, vol. 136, no. 4, pp. 629–641, 2009.
[6] V. K. Gangaraju and H. Lin, “MicroRNAs: key regulators of stem cells,” Nature Reviews Molecular Cell Biology, vol. 10, no. 2, pp. 116–125, 2009.
[7] A. Shenoy and R. H. Blelloch, “Regulation of microRNA function in somatic stem cell proliferation and differentiation,” Nature Reviews Molecular Cell Biology, vol. 15, no. 9, pp. 565–576, 2014.
[8] S. Yao, “MicroRNA biogenesis and their functions in regulating stem cell potency and differentiation,” Biological Procedures Online, vol. 18, p. 8, 2016.
[9] M. B. Clark, T. R. Mercer, G. Bussotti et al., “Quantitative gene profiling of long noncoding RNAs with targeted RNA sequencing,” Nature Methods, vol. 12, no. 4, pp. 339–342, 2015.
[10] M. Guttman, I. Amit, M. Garber et al., “Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals,” Nature, vol. 458, no. 7235, pp. 223–227, 2009.
[11] T. Derrien, R. Johnson, G. Bussotti et al., “The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression,” Genome Research, vol. 22, no. 9, pp. 1775–1789, 2012.
[12] J. J. Quinn and H. Y. Chang, “Unique features of long non-coding RNA biogenesis and function,” Nature Reviews Genetics, vol. 17, no. 1, pp. 47–62, 2016.
[13] J. L. Rinn and H. Y. Chang, “Genome regulation by long noncoding RNAs,” Annual Review of Biochemistry, vol. 81, pp. 145–166, 2012.
[14] T. Hung and H. Y. Chang, “Long noncoding RNA in genome regulation: prospects and mechanisms,” RNA Biology, vol. 7, no. 5, pp. 582–5, 2010.
[15] S. Geisler and J. Coller, “RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts,” Nature Reviews Molecular Cell Biology, vol. 14, no. 11, pp. 699–712, 2013.
[16] C. Carriero, L. Cinì, M. Biagioli et al., “Long non-coding antisense RNA controls Uchl1 translation through an embedded SINEB2 repeat,” Nature, vol. 491, no. 7424, pp. 454–457, 2012.
[17] C. Carrieri, L. Cinì, M. Biagioli et al., “Long non-coding antisense RNA controls Uchl1 translation through an embedded SINEB2 repeat,” Nature, vol. 491, no. 7424, pp. 454–457, 2012.
[18] M. A. Faghhihi, M. Zhang, J. Huang et al., “Evidence for natural antisense transcript-mediated inhibition of microRNA function,” Genome Biology, vol. 11, no. 5, article R56, 2010.
[19] F. Moreau, S. Chateauvieux, A. Gaigneaux, M. Dicato, and M. Diederich, “Long and short non-coding RNAs as regulators of hematopoietic differentiation,” International Journal of Molecular Sciences, vol. 14, no. 7, pp. 14744–14770, 2013.
[20] J. A. Heward and M. A. Lindsay, “Long non-coding RNAs in the regulation of the immune response,” Trends in Immunology, vol. 35, no. 9, pp. 408–419, 2014.
[21] B. Liu, L. Sun, Q. Lü et al., “A cytoplasmic NF-kappaB interacting long noncoding RNA blocks IkappaB phosphorylation and suppresses breast cancer metastasis,” Cancer Cell, vol. 27, no. 3, pp. 370–381, 2015.
[22] L. Wan, M. Sun, G. J. Liu et al., “Long noncoding RNA PVT1 promotes non-small cell lung cancer cell proliferation through epigenetically regulating LATS2 expression,” Molecular Cancer Therapeutics, vol. 15, no. 5, pp. 1082–1094, 2016.
[23] K. C. Wang and H. Y. Chang, “Molecular mechanisms of long noncoding RNAs,” Molecular Cell, vol. 43, no. 6, pp. 904–914, 2011.
[24] Y. Fang and M. J. Fullwood, “Roles, functions, and mechanisms of long non-coding RNAs in cancer,” Genomics, Proteomics & Bioinformatics, vol. 14, no. 1, pp. 42–54, 2016.
[25] V. Tripathi, J. D. Ellis, Z. Shen et al., “The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation,” Molecular Cell, vol. 39, no. 6, pp. 925–938, 2010.
[26] A. Rosa and M. Ballarino, “Long noncoding RNA regulation of Pluripotency,” Stem Cells International, vol. 2016, Article ID 1797692, 9 pages, 2016.
[27] R. B. Perry and I. Ulitsky, “The functions of long noncoding RNAs in development and stem cells,” Development, vol. 143, no. 21, pp. 3882–3894, 2016.
[28] S. J. Hafner, T. G. Talvard, and A. H. Lund, “Long noncoding RNAs in normal and pathological pluripotency,” Seminars in Cell & Developmental Biology, vol. 65, pp. 1–10, 2017.
[29] M. N. Cabili, C. Trapnell, L. Goff et al., “Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses,” Genes & Development, vol. 25, no. 18, pp. 1915–1927, 2011.
[30] D. M. Church, L. Goodstadt, L. W. Hillier et al., “Lineage-specific biology revealed by a finished genome assembly of the mouse,” PLoS Biology, vol. 7, no. 5, article e1000112, 2009.
[31] L. A. Wagner, C. J. Christensen, D. M. Dunn et al., "EGO, a novel, noncoding RNA gene, regulates eosinophil granule protein transcript expression," *Blood*, vol. 109, no. 12, pp. 5191–5198, 2007.

[32] S. Blackshaw, S. Harppavat, J. Trimarchi et al., "Genomic analysis of mouse retinal development," *PLoS Biology*, vol. 2, no. 9, article E247, 2004.

[33] N. A. Rapicavoli, E. M. Poth, and S. Blackshaw, "The long noncoding RNA RNC22 directly mouse retinal cell specification," *BMC Developmental Biology*, vol. 10, p. 49, 2010.

[34] M. Sone, T. Hayashi, H. Tarui, K. Agata, M. Takeichi, and S. Nakagawa, "The mRNA-like noncoding RNA Gomafu constitutes a novel nuclear domain in a subset of neurons," *Journal of Cell Science*, vol. 120, Part 15, pp. 2498–2506, 2007.

[35] J. Sheik Mohamed, P. M. Gaughwin, B. Lim, P. Robson, and L. Lipovich, "Conserved long noncoding RNAs transcriptionally regulated by Oct4 and Nanog modulate pluripotency in mouse embryonic stem cells," *RNA*, vol. 16, no. 2, pp. 324–337, 2010.

[36] Y. Chen, K. Wang, Y. G. Gong, S. K. Khoo, and R. Leach, "Roles of CDX2 and EOMES in human induced trophoblast progenitor cells," *Biochemical and Biophysical Research Communications*, vol. 431, no. 2, pp. 197–202, 2013.

[37] I. C. Scott, L. Anson-Cartwright, P. Riley, D. Reda, and J. C. W. He, C. Ingraham, L. Rising, S. Goderie, and S. Temple, "The HAND1 basic helix-loop-helix transcription factor regulates trophoblast differentiation via multiple mechanisms," *Molecular and Cellular Biology*, vol. 20, no. 2, pp. 530–541, 2000.

[38] A. Ralston, B. J. Cox, N. Nishioka et al., "Gata3 regulates trophoblast development downstream of Tead4 and in parallel to Cdx2," *Development*, vol. 137, no. 3, pp. 395–403, 2010.

[39] T. R. Mercer, I. A. Qureshi, S. Gokhan et al., "Long noncoding RNAs in neuronal-glial fate specification and oligodendrocyte lineage maturation," *BMC Neuroscience*, vol. 11, p. 14, 2010.

[40] W. He, C. Ingraham, L. Rising, S. Goderie, and S. Temple, "Multipotent stem cells from the mouse basal forebrain contribute to GABAergic neurons and oligodendrocytes to the cerebral cortex during embryogenesis," *The Journal of Neuroscience*, vol. 21, no. 22, pp. 8854–8862, 2001.

[41] N. Ishii, K. Ozaki, H. Sato et al., "Identification of a novel non-coding RNA, MIAT, that confers risk of myocardial infarction," *Journal of Human Genetics*, vol. 51, no. 12, pp. 1087–1099, 2006.

[42] C. Jin, Y. Zheng, Y. Huang, Y. Liu, L. Jia, and Y. Zhou, "Long non-coding RNA MIAT knockdown promotes osteogenic differentiation of human adipose-derived stem cells," *Cell Biology International*, vol. 41, no. 1, pp. 33–41, 2017.

[43] J. Feng, C. Bi, B. S. Clark, R. Mady, P. Shah, and J. D. Kohtz, "The Evf-2 noncoding RNA is transcribed from the Dlx-5/6 ultraconserved region and functions as a Dlx-2 transcriptional coactivator," *Genes & Development*, vol. 20, no. 11, pp. 1470–1484, 2006.

[44] P. Ji, S. Diederichs, W. Wang et al., "MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer," *Oncogene*, vol. 22, no. 39, pp. 8031–8041, 2003.

[45] D. B. Ritkin, "Latent transforming growth factor-beta (TGF-beta) binding proteins: orchestrators of TGF-beta availability," *The Journal of Biological Chemistry*, vol. 280, no. 9, pp. 7409–7412, 2005.

[46] B. Li, P. Chen, J. Qu et al., "Activation of LTB3 gene by a long noncoding RNA (lncRNA) MALAT1 transcript in mesenchymal stem cells from multiple myeloma," *The Journal of Biological Chemistry*, vol. 289, no. 42, pp. 29365–29375, 2014.

[47] M. Esquivel-Velazquez, P. Ostoaa-Saloma, M. I. Palacios-Arreola, K. E. Nava-Castro, J. I. Castro, and J. Morales-Montor, "The role of cytokines in breast cancer development and progression," *Journal of Interferon & Cytokine Research*, vol. 35, no. 1, pp. 1–16, 2015.

[48] Y. Han, L. Zhou, T. Wu et al., "Downregulation of lncRNA-MALAT1 affects proliferation and the expression of stemness markers in glioma stem cell line SHG139S," *Cellular and Molecular Neurobiology*, vol. 36, no. 7, pp. 1097–1107, 2016.

[49] F. Jiao, H. Hu, T. Han et al., "Long noncoding RNA MALAT-1 enhances stem cell-like phenotypes in pancreatic cancer cells," *International Journal of Molecular Sciences*, vol. 16, no. 4, pp. 6677–6693, 2015.

[50] S. P. Li, H. X. Xu, Y. Yu et al., "lncRNA HULC enhances epithelial-mesenchymal transition to promote tumorigenesis and metastasis of hepatocellular carcinoma via the miR-200a-3p/ZEBl signaling pathway," *Oncotarget*, vol. 7, no. 27, pp. 42431–42446, 2016.

[51] M. Wu, Z. Lin, X. Li et al., "HULC cooperates with MALAT1 to aggravate liver cancer stem cells growth through telomere repeat-binding factor 2," *Scientific Reports*, vol. 6, article 36045, 2016.

[52] M. Lin, E. Pedrosa, A. Shah et al., "RNA-Seq of human neurons derived from iPSCs reveals candidate long noncoding RNAs involved in neurogenesis and neuropsychiatric disorders," *PLoS One*, vol. 6, no. 9, article e23356, 2011.

[53] X. Y. Ma, J. H. Wang, J. L. Wang, C. X. Ma, X. C. Wang, and F. S. Liu, "Malat1 as an evolutionarily conserved lncRNA, plays a positive role in regulating proliferation and maintaining undifferentiated status of early-stage hematopoietic cells," *BMC Genomics*, vol. 16, p. 676, 2015.

[54] W. L. Gao, M. Liu, Y. Yang et al., "The imprinted H19 gene regulates human placental trophoblast cell proliferation via encoding miR-675 that targets nodal modulator 1 (NOMO1)," *RNA Biology*, vol. 9, no. 7, pp. 1002–1010, 2012.

[55] X. Cai and B. R. Cullen, "The imprinted H19 noncoding RNA is a primary microRNA precursor," *RNA*, vol. 13, no. 3, pp. 313–316, 2007.

[56] A. Keniry, D. Oxley, P. Monnier et al., "The H19 lincRNA is a developmental reservoir of miR-675 that suppresses growth and Igf1r," *Nature Cell Biology*, vol. 14, no. 7, pp. 659–665, 2012.

[57] P. Ohana, E. Kopf, O. Bibi et al., "The expression of the H19 gene and its function in human bladder carcinoma cell lines," *FEBS Letters*, vol. 454, no. 1-2, pp. 81–84, 1999.

[58] J. H. Yang, P. Shao, H. Zhou, Y. Q. Chen, and L. H. Qu, "deepBase: a database for deeply annotating and mining deep sequencing data," *Nucleic Acids Research*, vol. 38, Database issue, pp. D123–D130, 2010.

[59] F. Poirier, C. T. Chan, P. M. Timmons, E. J. Robertson, M. J. Evans, and P. W. Rigby, "The murine H19 gene is activated during embryonic stem cell differentiation in vitro and at the time of implantation in the developing embryo," *Development*, vol. 113, no. 4, pp. 1105–1114, 1997.
[60] A. Venkatraman, X. C. He, J. L. Thorvaldsen et al., "Maternal imprinting at the H19-Igfl2 locus maintains adult haematopoietic stem cell quiescence," Nature, vol. 500, no. 7462, pp. 345–349, 2013.

[61] X. Zhang, Z. Lian, C. Padden et al., "A myelopoesis-associated regulatory intergenic noncoding RNA transcript within the human HOXA cluster," Blood, vol. 113, no. 11, pp. 2526–2534, 2009.

[62] M. A. Arnaout, "Structure and function of the leukocyte adhesion molecules CD11/CD18," Blood, vol. 75, no. 5, pp. 1037–1050, 1990.

[63] N. Miyoshi, H. Wagaatsuwa, S. Wakana et al., "Identification of an imprinted gene, Meg3/Gtl2 and its human homologue MEG3, first mapped on mouse distal chromosome 12 and human chromosome 14q," Genes to Cells, vol. 5, no. 3, pp. 211–220, 2000.

[64] Y. Zhou, X. Zhang, and A. Klibanski, "MEG3 noncoding RNA: a tumor suppressor," Journal of Molecular Endocrinol., vol. 48, no. 3, pp. R45–R53, 2012.

[65] X. Shi, M. Sun, H. Liu, Y. Yao, and Y. Song, "Long non-coding RNAs: a new frontier in the study of human diseases," Cancer Letters, vol. 339, no. 2, pp. 159–166, 2013.

[66] P. J. Rugg-Gunn, A. C. Ferguson-Smith, and R. A. Pedersen, "Epigenetic status of human embryonic stem cells," Nature Genetics, vol. 37, no. 6, pp. 585–587, 2005.

[67] K. Nishino and A. Umezawa, "DNA methylation dynamics in human induced pluripotent stem cells," Human Cell, vol. 29, no. 3, pp. 97–100, 2016.

[68] C. F. Mo, F. C. Wu, K. Y. Tai et al., "Loss of non-coding RNA expression from the DLK1-DIO3 imprinted locus correlates with reduced neural differentiation potential in human embryonic stem cell lines," Stem Cell Research & Therapy, vol. 6, p. 1, 2015.

[69] R. Margueron and D. Reinberg, "The Polycomb complex PRC2 and its mark in life," Nature, vol. 469, no. 7330, pp. 343–349, 2011.

[70] P. Trojer and D. Reinberg, "Facultative heterochromatin: is there a distinctive molecular signature?," Molecular Cell, vol. 28, no. 1, pp. 1–13, 2007.

[71] S. Kaneko, R. Bonasio, R. Saldana-Meyer et al., "Interactions between JARID2 and noncoding RNAs regulate PRC2 recruitment to chromatin," Molecular Cell, vol. 53, no. 2, pp. 290–300, 2014.

[72] W. Zhuang, X. Ge, S. Yang et al., "Uregulation of IncRNA MEG3 promotes osteogenic differentiation of mesenchymal stem cells from multiple myeloma patients by targeting BMP4 transcription," Stem Cells, vol. 33, no. 6, pp. 1985–1997, 2015.

[73] Q. Wang, Y. Li, Y. Zhang et al., "LncRNA MEG3 inhibited osteogenic differentiation of bone marrow mesenchymal stem cells from postmenopausal osteoporosis by targeting miR-133a-3p," Biomedicine & Pharmacotherapy, vol. 89, pp. 1178–1186, 2017.

[74] C. M. Clemson, J. N. Hutchinson, S. A. Sara et al., "An architectural role for a nuclear noncoding RNA: NEAT1 RNA is essential for the structure of paraspeckles," Molecular Cell, vol. 33, no. 6, pp. 717–726, 2009.

[75] A. H. Fox, Y. W. Lam, A. K. Leung et al., "Paraspeckles: a novel nuclear domain," Current Biology, vol. 12, no. 1, pp. 13–25, 2002.

[76] L. L. Chen and G. G. Carmichael, "Altered nuclear retention of mRNAs containing inverted repeats in human embryonic stem cells: functional role of a nuclear noncoding RNA," Molecular Cell, vol. 35, no. 4, pp. 467–478, 2009.

[77] Y. T. Sasaki, T. Ideue, M. Sano, T. Mituyama, and T. Hirose, "MENepisolon/beta noncoding RNAs are essential for structural integrity of nuclear paraspeckles," Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 8, pp. 2525–2530, 2009.

[78] K. V. Prasanth, S. G. Prasanth, Z. Xuan et al., "Regulating gene expression through RNA nuclear retention," Cell, vol. 123, no. 2, pp. 249–263, 2005.

[79] H. Sunwoo, M. E. Dinger, J. E. Wilusz, P. P. Amaral, J. S. Mattick, and D. L. Spector, "MEN epsilon/beta nuclear-retained non-coding RNAs are up-regulated upon muscle differentiation and are essential components of paraspeckles," Genome Research, vol. 19, no. 3, pp. 347–359, 2009.

[80] R. Gernapudi, B. Wolfson, Y. Zhang et al., "MicroRNA 140 promotes expression of long noncoding RNA NEAT1 in adipogenesis," Molecular and Cellular Biology, vol. 36, no. 1, pp. 30–38, 2016.

[81] S. Loewer, M. N. Cabili, M. Guttman et al., "Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells," Nature Genetics, vol. 42, no. 12, pp. 1113–1117, 2010.

[82] Y. Wang, Z. Xu, J. Jiang et al., "Endogenous miRNA sponge lincRNA-RoR regulates Oct4, Nanog, and Sox2 in human embryonic stem cell self-renewal," Developmental Cell, vol. 25, no. 1, pp. 69–80, 2013.

[83] C. Mayer, M. Neubert, and I. Grummt, "The structure of NoRC-associated RNA is crucial for targeting the chromatin remodelling complex NoRC to the nucleolus," EMBO Reports, vol. 9, no. 8, pp. 774–780, 2008.

[84] C. Mayer, K. M. Schmitz, J. Li, I. Grummt, and R. Santoro, "Intergenic transcripts regulate the epigenetic state of rRNA genes," Molecular Cell, vol. 22, no. 3, pp. 351–361, 2006.

[85] N. Savic, D. Bar, S. Leone et al., "lncRNA maturation to initiate heterochromatin formation in the nucleolus is required for exit from pluripotency in ESCs," Cell Stem Cell, vol. 15, no. 6, pp. 720–734, 2014.

[86] S. A. Korneev, E. I. Korneeva, M. A. Lagarkova, S. L. Kiselev, G. Critchley, and M. O'Shea, "Novel noncoding antisense RNA transcribed from human anti-NOS2A locus is differentially regulated during neuronal differentiation of embryonic stem cells," RNA, vol. 14, no. 10, pp. 2030–2037, 2008.

[87] D. Y. Zhu, S. H. Liu, H. S. Sun, and Y. M. Lu, "Expression of inducible nitric oxide synthase after focal cerebral ischemia stimulates neurogenesis in the adult rodent dentate gyrus," The Journal of Neuroscience, vol. 23, no. 1, pp. 223–229, 2003.

[88] M. Guttman, J. Donaghey, B. W. Carey et al., "LincRNA-RoR regulates Oct4, Nanog, and Sox2 in human embryonic stem cell self-renewal," Developmental Cell, vol. 35, no. 1, pp. 720–734, 2014.

[89] T. Zhang, C. Cao, D. Wu, and L. Liu, "LncRNA maturation to initiate heterochromatin formation in the nucleolus is required for exit from pluripotency in ESCs," Cell Stem Cell, vol. 15, no. 6, pp. 720–734, 2014.

[90] S. A. Korneeva, E. I. Korneeva, M. A. Lagarkova, S. L. Kiselev, G. Critchley, and M. O'Shea, "Novel noncoding antisense RNA transcribed from human anti-NOS2A locus is differentially regulated during neuronal differentiation of embryonic stem cells," RNA, vol. 14, no. 10, pp. 2030–2037, 2008.

[91] D. Y. Zhu, S. H. Liu, H. S. Sun, and Y. M. Lu, "Expression of inducible nitric oxide synthase after focal cerebral ischemia stimulates neurogenesis in the adult rodent dentate gyrus," The Journal of Neuroscience, vol. 23, no. 1, pp. 223–229, 2003.

[92] M. Guttman, J. Donaghey, B. W. Carey et al., "LincRNA-RoR regulates Oct4, Nanog, and Sox2 in human embryonic stem cell self-renewal," Developmental Cell, vol. 35, no. 1, pp. 720–734, 2014.

[93] T. Zhang, C. Cao, D. Wu, and L. Liu, "LncRNA maturation to initiate heterochromatin formation in the nucleolus is required for exit from pluripotency in ESCs," Cell Stem Cell, vol. 15, no. 6, pp. 720–734, 2014.
H. Fong, K. A. Hohenstein, and P. J. Donovan, “Regulation of self-renewal and pluripotency by Sox2 in human embryonic stem cells,” *Stem Cells*, vol. 26, no. 8, pp. 1931–8, 2008.

J. Fantes, N. K. Ragge, S. A. Lynch et al., “Mutations in SOX2 cause anophthalmia,” *Nature Genetics*, vol. 33, no. 4, pp. 461–463, 2003.

A. Shahryari, M. S. Jazi, N. M. Samaei, and S. J. Mowla, “Long non-coding RNA SOX2OT: expression signature, splicing patterns, and emerging roles in pluripotency and tumorigenesis,” *Frontiers in Genetics*, vol. 6, p. 196, 2015.

P. P. Amaral, C. Neyt, S. J. Wilkins et al., “Complex architecture and regulated expression of the Sox2ot locus during vertebrate development,” *RNA*, vol. 15, no. 11, pp. 2013–2027, 2009.

J. H. Ng and H. H. Ng, “LincRNAs join the pluripotency alliance,” *Nature Genetics*, vol. 42, no. 12, pp. 1035-1036, 2010.

S. Ounzain, R. Micheletti, C. Arnan et al., “CARMEN, a human super enhancer-associated long noncoding RNA controlling cardiac specification, differentiation and homeostasis,” *Journal of Molecular and Cellular Cardiology*, vol. 89, Part A, pp. 98–112, 2015.

C. T. Ong and V. G. Corces, “Enhancers: emerging roles in cell fate specification,” *EMBO Reports*, vol. 13, no. 5, pp. 423–430, 2012.

S. Ounzain, I. Pezzuto, R. Micheletti et al., “Functional importance of cardiac enhancer-associated noncoding RNAs in heart development and disease,” *Journal of Molecular and Cellular Cardiology*, vol. 76, pp. 55–70, 2014.

S. Y. Ng, R. Johnson, and L. W. Stanton, “Human long non-coding RNAs promote pluripotency and neuronal differentiation by association with chromatin modifiers and transcription factors,” *The EMBO Journal*, vol. 31, no. 3, pp. 522–533, 2012.

Z. Gao, K. Ure, P. Ding et al., “The master negative regulator REST/NRSF controls adult neurogenesis by restraining the neurogenic program in quiescent stem cells,” *The Journal of Neuroscience*, vol. 31, no. 26, pp. 9772–9786, 2011.

H. Kamma, H. Horiguchi, L. Wan et al., “Molecular characterization of the hnRNP A2/B1 proteins: tissue-specific expression and novel isoforms,” *Experimental Cell Research*, vol. 246, no. 2, pp. 399–411, 1999.

D. S. Castro and F. Guillemot, “Old and new functions of pro-neural factors revealed by the genome-wide characterization of their transcriptional targets,” *Cell Cycle*, vol. 10, no. 23, pp. 4026–4031, 2011.

M. A. Petryniak, G. B. Potter, D. H. Rowitz, and J. L. Rubenstein, “Dlx1 and Dlx2 control neuronal versus oligodendroglial cell fate acquisition in the developing forebrain,” *Neuron*, vol. 55, no. 3, pp. 417–433, 2007.

S. Y. Ng, G. K. Bogu, B. S. Soh, and L. W. Stanton, “The long noncoding RNA RMST interacts with SOX2 to regulate neurogenesis,” *Molecular Cell*, vol. 51, no. 3, pp. 349–359, 2013.

X. Lu, F. Sachs, L. Ramsay et al., “The retrovirus HERVH is a long noncoding RNA required for human embryonic stem cell identity,” *Nature Structural & Molecular Biology*, vol. 21, no. 4, pp. 423–425, 2014.

A. Trounson and C. McDonald, “Stem cell therapies in clinical trials: progress and challenges,” *Cell Stem Cell*, vol. 17, no. 1, pp. 11–22, 2015.